Update from ASU Biodesign's Dr. Raymond DuBois
Dr. Ray DuBois , M.D., Ph.D. Dr. DuBois is a world-renowned physician-scientist who has devoted his career to understanding the linkages between inflammation and cancer, particularly colon cancer. He assumed his new role as Executive Director of the Biodesign Institute in December of 2012, coming by way of Houston as provost of the prestigious M.D. Anderson Cancer Center.
Phoenix Biomedical Campus: Health Sciences Education Building
Tour the newest addition to the Phoenix Biomedical Campus - the Health Sciences Education Building. This spectacular copper-faced structure will play a critical role in the education of the next generation of science and health professionals. The 268,000 square-foot building is home to the University of Arizona and Northern Arizona University health sciences programs.
Building a Medical School
A dream come true for downtown Phoenix; Building a new medical school For six local doctors, the creation of what is now one of the newest medical colleges in the nation seemed a distant dream. These seasoned professionals have invested many years, personal and professional commitment, expertise and downright tenacity, to make this campus and this college a reality. All contributed from their respective fields and their respective hospitals. All were teachers and saw the need for the development of the University of Arizona College of Medicine - Phoenix. Read more at: http://phoenixmed.arizona.edu
Harry A. George, 2012 Bioscience Leader of the Year
For close to four decades, Harry George has been creating, capitalizing, and operating rapid-growth technology companies. A quiet, action oriented leader. Harry has consistently driven Arizona’s bioscience and technology sectors forward by acting on his vision with commitment, dedication, and determination. In recognition of his service and accomplishments, Harry A. George is the 2012 Jon W. McGarity Bioscience Leader of the Year
2012 Fast Lane Award Winner - the Critical Path Institute
With both drug development costs and healthcare costs at record heights, how can we drive innovation and lifesaving discoveries down the path faster. That is the question the team at the Critical Path Institute (C-Path) asks every day. Critical Path Institute , a healthcare change agent and leading center of excellence for collaborative scientific innovation, was formed with visionary support from the State of Arizona, UA, Science Foundation Arizona, FDA and the community at large. Its mission: to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. There is no other entity in the country that does what C-Path does. C-Path Milestones and “firsts” include: 1st preclinical safety biomarkers (7) qualified by FDA and its counterparts in Europe and Japan – biomarkers used to detect drug-induced kidney injury earlier and more precisely. 1st CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard enables aggregating and easier FDA review of Alzheimer’s clinical trial data. 1st and largest open database of CDISC aggregated Alzheimer’s clinical trial data (6,100 patients, 22 clinical trials) enabling scientists to look for means to detect disease earlier and understand disease progression based on age, sex, genotypes. 1st drug-disease trial model and clinical trial simulation tool submitted/under review by FDA – model enables scientists to better design Alzheimer’s clinical trials. 1st imaging biomarker for trial enrichment qualified by EMA – biomarker used to select patients in very early stages of Alzheimer’s for inclusion in clinical trials. C-Path brings together stakeholders to create what no one company, university, or government agency could do alone: 6 global consortia with 1,000 scientists, 41 companies, government agencies, patient groups, and academia to collaborate on “tools” to help drug development and focus on drug safety, drug effectiveness, diseases of the brain, developing new imaging biomarkers, and testing drug combinations. C-Path’s collaborative work is just beginning to translate knowledge of disease and human physiology into safe and effective therapies.
2012 State of the Industry: John D. Carroll of FierceBiotech
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered virtually every aspect of the global drug development industry over the past decade. His work includes the popular Fierce 15, which recognizes the most innovative private companies in the business each year. His daily reports keep more than 100,000 subscribers around the world clued in to the latest developments on deals, data and industry trends. Carroll plans to address the biggest influences affecting the fast-changing biopharma industry and what it means to biotech executives in Arizona.